Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – September 19, 2024) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus’s management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company’s auditors. Detailed voting results for the election of directors are set out in the table below. Name For Against Ken d’Entremont 99.02% (7,892,141) 0.98% (77,869) Harmony Garges 98.69% (7,865,796) 1.31% (104,214) Benoit Gravel 98.70% (7,866,796) 1.30% (103,214) Michael Mueller
99.01% (7,890,796) 0.99% (79,214) Stephen Nelson 99.01% (7,890,929) 0.99% (79,081) Nancy Phelan 98.66% (7,862,929) 1.34% (107,081) Menassie Taddese 98.69% (7,865,929) 1.31% (104,081) Shareholders also cast 8,922,492 (99.32%) votes for and withheld 61,521 (0.68%) votes from the appointment of PricewaterhouseCoopers LLP as the company’s auditors. All proposals were therefore approved. A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.com. About Medexus Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus’s current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company’s corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.
These statements are based on the company’s current expectations, beliefs, assumptions, and information available to it. Forward-looking statements are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, changes in economic conditions, competition, regulatory changes, technological advancements, and the company’s ability to execute its business strategy.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223941 SOURCE: Medexus Pharmaceuticals Inc.
news is a contributor at WhySkin. We are committed to providing well-researched, accurate, and valuable content to our readers.
